MK6482-022: A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare Efficacy and Safety of Belzutifan (MK-6482) plus Pembrolizumab Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post-Nephrectomy